<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">86260</article-id><article-id pub-id-type="doi">10.7554/eLife.86260</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Autonomous metabolic reprogramming and oxidative stress characterize endothelial dysfunction in acute myocardial infarction</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-311421"><name><surname>Zodda</surname><given-names>Erika</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4536-9106</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311422"><name><surname>Tura-Ceide</surname><given-names>Olga</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311423"><name><surname>Mills</surname><given-names>Nicholas L</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311424"><name><surname>Tarragó-Celada</surname><given-names>Josep</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311425"><name><surname>Carini</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-37783"><name><surname>Thomson</surname><given-names>Timothy M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4670-9440</contrib-id><email>titbmc@ibmb.csic.es</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund10"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes" id="author-212137"><name><surname>Cascante</surname><given-names>Marta</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2062-4633</contrib-id><email>martacascante@ub.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund11"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021018s57</institution-id><institution>Department of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05t8khn72</institution-id><institution>Institute for Molecular Biology of Barcelona, National Research Council (IBMB-CSIC)</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02g87qh62</institution-id><institution>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBER-EDH)</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021018s57</institution-id><institution>Department of Pulmonary Medicine, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS); University of Barcelona</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02g87qh62</institution-id><institution>Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES)</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03nzegx43</institution-id><institution>Department of Pulmonary Medicine, Dr. Josep Trueta University Hospital de Girona, Santa Caterina Hospital de Salt and Girona Biomedical Research Institute (IDIBGI)</institution></institution-wrap><addr-line><named-content content-type="city">Girona</named-content></addr-line><country>Spain</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>University/BHF Centre for Cardiovascular Science, University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00wjc7c48</institution-id><institution>Department of Pharmaceutical Sciences, Università degli Studi di Milano</institution></institution-wrap><addr-line><named-content content-type="city">Milan</named-content></addr-line><country>Italy</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yczjf25</institution-id><institution>Universidad Peruana Cayetano Heredia</institution></institution-wrap><addr-line><named-content content-type="city">Lima</named-content></addr-line><country>Peru</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/021018s57</institution-id><institution>Institute of Biomedicine (IBUB), University of Barcelona</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>University of Melbourne</institution></institution-wrap><addr-line><named-content content-type="city">Melbourne</named-content></addr-line><country>Australia</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Bhargava</surname><given-names>Balram</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0492wrx28</institution-id><institution>Indian Council of Medical Research</institution></institution-wrap><addr-line><named-content content-type="city">New Delhi</named-content></addr-line><country>India</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>28</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e86260</elocation-id><history><date date-type="received" iso-8601-date="2023-01-18"><day>18</day><month>01</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-08-01"><day>01</day><month>08</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2023-03-01"><day>01</day><month>03</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.02.28.530418"/></event></pub-history><permissions><copyright-statement>© 2023, Zodda et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Zodda et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-86260-v2.pdf"/><abstract><p>Compelling evidence has accumulated on the role of oxidative stress on the endothelial cell (EC) dysfunction in acute coronary syndrome. Unveiling the underlying metabolic determinants has been hampered by the scarcity of appropriate cell models to address cell-autonomous mechanisms of EC dysfunction. We have generated endothelial cells derived from thrombectomy specimens from patients affected with acute myocardial infarction (AMI) and conducted phenotypical and metabolic characterizations. AMI-derived endothelial cells (AMIECs) display impaired growth, migration, and tubulogenesis. Metabolically, AMIECs displayed augmented ROS and glutathione intracellular content, with a diminished glucose consumption coupled to high lactate production. In AMIECs, while PFKFB3 protein levels of were downregulated, PFKFB4 levels were upregulated, suggesting a shunting of glycolysis towards the pentose phosphate pathway, supported by upregulation of G6PD. Furthermore, the glutaminolytic enzyme GLS was upregulated in AMIECs, providing an explanation for the increase in glutathione content. Finally, AMIECs displayed a significantly higher mitochondrial membrane potential than control ECs, which, together with high ROS levels, suggests a coupled mitochondrial activity. We suggest that high mitochondrial proton coupling underlies the high production of ROS, balanced by PPP- and glutaminolysis-driven synthesis of glutathione, as a primary, cell-autonomous abnormality driving EC dysfunction in AMI.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cardiovascular diseases</kwd><kwd>endothelial</kwd><kwd>metabolism</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution>CIBER Carlos III National Institute of Health</institution></institution-wrap></funding-source><award-id>CIBEREHD-CB17/04/00023</award-id><principal-award-recipient><name><surname>Thomson</surname><given-names>Timothy M</given-names></name><name><surname>Cascante</surname><given-names>Marta</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>CIBER Carlos III National Institute of Health</institution></institution-wrap></funding-source><award-id>CIBERES-CP17/00114</award-id><principal-award-recipient><name><surname>Tura-Ceide</surname><given-names>Olga</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Spanish Ministerio de Economia y Competitividad</institution></institution-wrap></funding-source><award-id>PID2019-107139RB-C21</award-id><principal-award-recipient><name><surname>Thomson</surname><given-names>Timothy M</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Spanish Ministerio de Economia y Competitividad</institution></institution-wrap></funding-source><award-id>PID2020-115051RB-I00</award-id><principal-award-recipient><name><surname>Cascante</surname><given-names>Marta</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>Generalitat de Catalunya-AGAUR</institution></institution-wrap></funding-source><award-id>2021 SGR00350</award-id><principal-award-recipient><name><surname>Cascante</surname><given-names>Marta</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>Generalitat de Catalunya-AGAUR</institution></institution-wrap></funding-source><award-id>2021 SGR1490</award-id><principal-award-recipient><name><surname>Thomson</surname><given-names>Timothy M</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>RE/18/5/34216</award-id><principal-award-recipient><name><surname>Mills</surname><given-names>Nicholas L</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>RG/20/10/34966</award-id><principal-award-recipient><name><surname>Mills</surname><given-names>Nicholas L</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>CH/F/21/90010</award-id><principal-award-recipient><name><surname>Mills</surname><given-names>Nicholas L</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010665</institution-id><institution>H2020 Marie Skłodowska-Curie Actions</institution></institution-wrap></funding-source><award-id>MOGLYNET H2020-MSCA-ITN-EJD grant (agreement No 675527)</award-id><principal-award-recipient><name><surname>Cascante</surname><given-names>Marta</given-names></name><name><surname>Thomson</surname><given-names>Timothy M</given-names></name><name><surname>Zodda</surname><given-names>Erika</given-names></name><name><surname>Carini</surname><given-names>Marina</given-names></name><name><surname>Tura-Ceide</surname><given-names>Olga</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003741</institution-id><institution>Catalan Institution for Research and Advanced Studies</institution></institution-wrap></funding-source><award-id>ICREA Academia Prize 2021, 2014SGR1017</award-id><principal-award-recipient><name><surname>Cascante</surname><given-names>Marta</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution>Plataforma Temática Interdisciplinar - Salud Global</institution></institution-wrap></funding-source><award-id>SGL2103019</award-id><principal-award-recipient><name><surname>Zodda</surname><given-names>Erika</given-names></name><name><surname>Thomson</surname><given-names>Timothy M</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004837</institution-id><institution>Ministerio de Ciencia e Innovación</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Zodda</surname><given-names>Erika</given-names></name><name><surname>Thomson</surname><given-names>Timothy M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Acute myocardial infarction patient-derived endothelial cells display a strong mitochondrial proton coupling with excess ROS production, enhanced glutamine metabolism and a carbon source switch from glucose to glutamine.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Cardiovascular diseases are the leading cause of death worldwide and comprise a range of syndromes affecting the functionality of the heart and blood vessels (<xref ref-type="bibr" rid="bib45">Smolders et al., 2018</xref>; <xref ref-type="bibr" rid="bib49">Townsend et al., 2022</xref>). Vascular dysfunction is believed to be a primary factor in the onset and progression of atherosclerosis and other vascular-related disorders. In this study, we focus our attention on a specific vascular disease, AMI, a major cause of morbidity in the Western world (<xref ref-type="bibr" rid="bib49">Townsend et al., 2022</xref>). AMI occurs as a consequence of coronary occlusion, generally from a thrombus superimposed on an ulcerated or unstable atherosclerotic plaque (<xref ref-type="bibr" rid="bib2">Badimon et al., 2012</xref>; <xref ref-type="bibr" rid="bib45">Smolders et al., 2018</xref>). The endothelium plays a pivotal role in the development of AMI, both preceding atherogenesis and predisposing to thrombosis (<xref ref-type="bibr" rid="bib39">Previtali et al., 2011</xref>).</p><p>Emerging evidence indicates that pathological blood vessel responses and endothelial dysfunction are associated with metabolic alterations in ECs (<xref ref-type="bibr" rid="bib6">Botts et al., 2021</xref>; <xref ref-type="bibr" rid="bib35">Moreno-Viedma et al., 2016</xref>). Thus, to identify new strategies to limit CVD progression in at risk/affected patients, metabolic alterations underlying impaired endothelial cells functions require appropriate patient-derived cell models (<xref ref-type="bibr" rid="bib22">Gallogly et al., 2021</xref>). As such, the study of endothelial metabolism and mitochondrial function may be central to unveiling fundamental mechanisms of cardiovascular pathogenesis, and to identify novel critical metabolic biomarkers and therapeutic targets.</p><p>Here, we have approached the study of endothelial cells dysfunction and metabolic alterations associated with AMI, by using coronary endothelial cells isolated and cultured from thrombectomy specimens obtained from patients affected with AMI. Our observations point to pharmacologically actionable cell-autonomous metabolic dysfunction in these cells.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>AMIECs display impaired growth and migration</title><p>AMIECs were isolated from coronary atherothrombotic specimens from eight patients undergoing percutaneous coronary intervention with thrombectomy for the treatment of acute ST-segment elevation myocardial infarction (STEMI). Hereafter, the eight patient-derived cell lines are designated CE followed by two digits (CE45, CE46, CE48, CE51, CE52, CE53, CE60, CE61).</p><p>At 80% confluence, AMIECs presented the expected shape and appeared similar to control HCAECs (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), as expected for bonafide endothelial cells grown under equivalent conditions. The endothelial nature of these cells was confirmed by Western blotting for the expression of the endothelial markers, V-CAM1 (vascular cell adhesion protein 1, CD-106), PECAM-1 (platelet endothelial cell adhesion molecule, CD31), CD-34, and CD-105 (endoglin) (<xref ref-type="fig" rid="fig1">Figure 1B and C</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>AMI-derived endothelial cells (AMIECs) display impaired growth and migration.</title><p>(<bold>A</bold>) Bright field images of human coronary artery endothelial cells (HCAECs) (left panels) vs. AMIECs (right panels), captured under 10 x and 20 x objectives on a Leica microscope. (<bold>B</bold>) Representative Western blotting experiments for the endothelial markers, PECAM-1, V-CAM1, CD-34, and CD-10 (<xref ref-type="supplementary-material" rid="fig1sdata1 fig1sdata2">Figure 1—source data 1 and 2</xref>). (<bold>C</bold>) Growth rate of AMIECs and control HCAEC, expressed as fold change relative to initial cell number seeded. Error bars represent mean ± SD (n=3). (<bold>D</bold>) Cell cycle analysis of AMIECs and HCAECs under logarithmic growth conditions, showing a non-significant trend for AMIECs to accumulate G1 phase as compared to HCAEC. Error bars represent mean ± SD (n=3). (<bold>E</bold>) Representative images of Mito C-treated migration in scratch wound assays, showing reduced migration of AMIECs compared to control HCAECs. (<bold>F</bold>) Quantification of cell migration in scratch wound assays, represented as % of wound closure. Values are mean ± SD (n=3). Student’s t-test significance values were calculated for AMIECs vs. HCAEC: *p≤0.05 **p≤0.01, ***p≤0.001.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Western blotting experiments for endothelial markers.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86260-fig1-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Western blotting experiments for endothelial markers.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86260-fig1-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86260-fig1-v2.tif"/></fig><p>Because optimal growth conditions for endothelial cells entail maintaining them at a relatively high confluence, they cannot be kept in culture for prolonged periods at an optimal confluence (70–80%), as overgrowth will cause cells to pile up and lose their physiological monolayer growth pattern. Therefore, cell growth monitoring was limited to 168 hr. Under these conditions, all AMIECs consistently displayed slower growth rates as compared to control HCAECs (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Indeed, after 168 hr, while control HCAECs had reached a plateau in their growth, AMIECs continued to proliferate exponentially, albeit at slow rates, without reaching saturation.</p><p>Given these results, we determine the cell cycle distribution of these cells by flow cytometry 24 hr after seeding, the point of maximum growth in the control HCAECs. Somewhat contrary to our expectations, we observed no significant differences in the distribution of cell cycle phases between AMIECs and control cells (<xref ref-type="fig" rid="fig1">Figure 1E</xref>), except for a modest tendency, without reaching statistical significance, of AMIECs to accumulate in the G1 phase relative to HCAECs. The slow growth rate, in conjunction with unaltered cell cycle phase distribution, of AMIECs suggests an overall slowing down of growth that affects equally all phases of the cell cycle.</p><p>In wound-healing migration assays, control HCAECs achieved a complete closure of the wound after 24 hr of seeding (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). In contrast, three AMIECs displayed wound closure rates below 50%, four others about 60%, and only one about 80% after 24 hr of migration under the same conditions (<xref ref-type="fig" rid="fig1">Figure 1G</xref>).</p><p>These results indicate that AMI patient-derived coronary endothelial cells are dysfunctional in major cell-autonomous processes, namely growth and migration.</p></sec><sec id="s2-2"><title>Defective tubulogenesis in AMIECs</title><p>The ability to migrate is a critical function of healthy endothelial cells, which can migrate while branching from existing blood vessels toward sources of angiogenic stimuli, guided by tip cells. Impairment in this fundamental endothelial function is considered a hallmark of vascular diseases (<xref ref-type="bibr" rid="bib14">De Bock et al., 2013</xref>). Thus, we next assessed the tubulogenic potential of AMIECs, as an indicator of their vasculogenic (angiogenic) potential. Control HCAECs and AMIECs were cultured under conditions that favor tubulogenesis, and branching points scored after 12 hr of switching to a tubulogenic medium containing VEGF (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). While control HCAECs averaged 80 branching points, AMIECs displayed a significantly reduced tubulogenic potential, evident both as a diminished number of branching points and as shorter and fragmented tubes as compared to control cells (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The branching capacity of the AMIECs derived from different patients was linearly correlated (R<sup>2</sup>=0.67) with their ability to migrate (<xref ref-type="fig" rid="fig2">Figure 2C</xref>) regardless of their growth rates suggesting that the deficient tubulogenesis or sprouting of these cells is linked to a defect in their migration properties, rather than to abnormal proliferation or survival.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Defective tubulogenesis of AMI-derived endothelial cells (AMIECs).</title><p>(<bold>A</bold>) Endothelial tube network formation after 12 hr of VEGF stimulation. Shown are representative bright field images from triplicate experiments. Scale bar = 100 μm. (<bold>B</bold>) Tube branch point quantification of images from experiments performed as in (<bold>A</bold>). Values are mean ± SD (n=3). Student’s t-test significance values were calculated for AMIECs vs. human coronary artery endothelial cell (HCAEC): *p≤0.05 **p≤0.01, ***p≤0.001. (<bold>C</bold>) Correlation between relative migration (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) and tubulogenesis in AMIECs and HCAECs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86260-fig2-v2.tif"/></fig></sec><sec id="s2-3"><title>AMIECs display low glucose consumption and high lactate production</title><p>The above characterization points to cell-autonomous defects in AMI patient-derived endothelial cells that compromise their ability to proliferate, migrate, and form branched tubular structures. We next tackled the hypothesis that the metabolic features of these cells might be associated with at least part of the observed phenotypes. To assess nutrient and metabolite consumption and production rates, the concentration of selected metabolites in culture media was determined. We focused on glucose as the major carbon source of the glycolytic pathway, lactate as the main metabolic end-product of glycolysis, and glutamine/glutamate as alternative sources of carbon metabolism and major providers of mitochondrial anaplerosis. We found that 6 out of the 8 AMIECs consumed glucose at significantly lower rates than control HCAECs (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), which may reconcile with the lower growth rates of patient-derived cells, while two patient-derived cell lines consumed more glucose than control cells. Remarkably, all AMIECs displayed a strong production of lactate, comparable or superior to control cells, regardless of their levels of glucose uptake (<xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>AMI-derived endothelial cells (AMIECs) display low glucose consumption and high lactate production.</title><p>(<bold>A</bold>) Glucose consumption and Lactate production have been measured after 48 hr. (<bold>B</bold>) Conversion rate of glucose to lactate. Error bars represent mean ± SD (n=3). Student’s t-test significance values were calculated for AMIECs vs. Human coronary artery endothelial cell (HCAECs): *p≤0.05 **p≤0.01, and ***p≤0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86260-fig3-v2.tif"/></fig><p>Two of the AMIECs, CE-45, and CE-61, consumed high levels of glucose and displayed robust lactate production (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>), and thus, it may be assumed that lactate is produced through glycolysis. The cells may also be hypothesized to be under a Warburg effect. However, their slow rates of proliferation stand in contrast to the rapid proliferation phenotypes seen in other cell types displaying a Warburg effect, such as cancer cells. On the other hand, the remaining six patient-derived endothelial cell lines, also slow growers, showed high levels of lactate production in spite of low glucose consumption (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>). This uncoupling of lactate production from glycolysis suggests the existence of an alternative source of lactate in these cells. In this regard, it is worth noting that glutaminolysis also produces lactate, in a pathway that involves the oxidation of glutamine to malate and then to pyruvate by the malic enzyme (ME), followed by conversion to lactate by the action of LDH-A (<xref ref-type="bibr" rid="bib8">Brooks, 2018</xref>).</p></sec><sec id="s2-4"><title>AMIECs shunt glycolysis towards PPP and NADPH generation</title><p>The low glucose uptake observed in 6 out of the 8 patient-derived endothelial cell lines prompted us to explore the expression of key enzymes in the glycolytic pathway. Under normal conditions, endothelial cells rely mainly on glycolysis to generate the energy required for their functions (<xref ref-type="bibr" rid="bib14">De Bock et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Dromparis and Michelakis, 2013</xref>; <xref ref-type="bibr" rid="bib23">Goveia et al., 2014</xref>). A key rate-limiting enzyme in this pathway is phosphofructokinase 1 (PFK1), responsible for the phosphorylation of fructose-6-phosphate (F-6-P) to fructose-1,6-phosphate (F-1,6-P) in an ATP-dependent reaction. PFK1 is allosterically activated by fructose-2,6-bisphosphate (F-2,6-BP), produced from F-6-P through the catalytic activity of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases encoded in mammals by paralogs PFKFB1, PFKFB2, PFKFB3, PFKFB4 and TP53-induced glycolysis and apoptosis regulator (TIGAR) (<xref ref-type="bibr" rid="bib4">Bensaad et al., 2006</xref>; <xref ref-type="bibr" rid="bib19">Eelen et al., 2018</xref>). These are bifunctional enzymes bearing, on the same polypeptide, an N-terminal 6-phosphofructo-2-kinase domain, and a C-terminal fructose 2,6-bisphosphatase domain. Given its relative kinase and bisphosphatase activities, PFKFB3 is a preferred target to inhibit glycolysis over other isoforms in this family of enzymes. PFKFB3 has been described to play a significant role in the glycolytic activity of pathological ECs, and its inhibition dramatically abrogates their proliferation and migration (<xref ref-type="bibr" rid="bib32">Li et al., 2019</xref>; <xref ref-type="bibr" rid="bib41">Schoors et al., 2014</xref>).</p><p>We determined PFKFB3 protein levels by Western blotting, finding significantly lower levels in 7 out of the 8 AMIECs, as compared to control HCAECs (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>), consistent with their lower glucose uptake. In fact, one of the two patient-derived cell lines with high glucose uptake, CE-45, expressed PFKFB3 at levels close to those of control cells (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>), thus reinforcing the notion that cell lines with low glucose uptake have low rates of glycolysis. This may also help explain, at least in part, the low proliferation rates, migration capacity, and tubulogenic activity of these cells, as these processes require robust glycolysis.</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>AMI-derived endothelial cells (AMIECs) shunt glycolysis towards pentose phosphate pathway (PPP) and NADPH generation.</title><p>(<bold>A</bold>) Representative Western blotting of PFKFB3 and PFKFB4 in AMIECs and human coronary artery endothelial cells (HCAECs) (<xref ref-type="supplementary-material" rid="fig4sdata1 fig4sdata2">Figure 4—source data 1</xref> ). (<bold>B</bold>) Quantification of band intensities for PFKFB3 and PFKFB4 in triplicate western blotting experiments, normalized to β-actin band intensities. Values are mean ± SD (n=3). (<bold>C</bold>) Representative Western blotting for glucose-6-phosphate dehydrogenase (G6PD) in AMIECs and HCAECs (<xref ref-type="supplementary-material" rid="fig4sdata2">Figure 4—source data 2</xref>). (<bold>D</bold>) Quantification of band intensities for G6PD in triplicate Western blotting experiments, normalized to β-actin band intensities. (<bold>E</bold>) G6PD enzyme activities normalized to intracellular protein content (n=3). (<bold>F</bold>) Reactive oxygen species (ROS) levels are determined by flow cytometry. Results are expressed as the mean fluorescent intensity. (<bold>G</bold>) Total intracellular reduced glutathione content. Values are normalized to cellular protein concentration. Error bars represent mean ± SD (n=3). For all experiments, Student’s t-test significance values were calculated for AMIECs vs. HCAECs: *p≤0.05 **p≤0.01, and ***p≤0.001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Western blotting of PFKFB3 and PFKFB4 in AMIECs and HCAECs.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86260-fig4-data1-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title>Western blotting for G6PD in AMIECs and HCAECs.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86260-fig4-data2-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86260-fig4-v2.tif"/></fig><p>We also determined PFKFB4 protein levels, finding significantly higher levels of expression in AMIECs compared to control cells (<xref ref-type="fig" rid="fig4">Figure 4A and B</xref>). Low levels of PFKFB3 expression coupled with high levels of PFKFB4 expression in AMI patient-derived cells predict a redirection of glucose-6-phosphate (G6P) towards the PPP. As a consequence, we would expect (1) increased production of NADPH-reducing equivalents through the oxidative branch of the PPP (<xref ref-type="bibr" rid="bib13">Dasgupta et al., 2018</xref>; <xref ref-type="bibr" rid="bib40">Ros et al., 2017</xref>) and (2) increased production of ribose-5-phosphate through the non-oxidative branch, for de novo synthesis of nucleotides as well as acetyl-CoA carboxylase 1 activation and lipogenesis (by inhibiting activation of liver kinase B1/AMPK signaling). The NADPH-reducing equivalents produced through the non-oxidative branch afford the maintenance of redox homeostasis by scavenging ROS (<xref ref-type="bibr" rid="bib3">Benito et al., 2017</xref>; <xref ref-type="bibr" rid="bib31">Li et al., 2014</xref>; <xref ref-type="bibr" rid="bib46">Sun et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Xia et al., 2017</xref>). The nucleotides supplied through the non-oxidative branch of the PPP can be used for DNA synthesis in proliferating cells, and also in DNA damage repair (<xref ref-type="bibr" rid="bib5">Bester et al., 2011</xref>).</p><p>In light of these predictions, we determined the expression level and activity of glucose-6-phosphate dehydrogenase (G6PD), the rate-limiting enzyme of the oxidative branch of the PPP. Consistently, we found significantly higher levels of G6PD in AMIECs than in control cells (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>). Likewise, AMIECs displayed higher levels of G6PD enzyme activity than control cells (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). These results support an enhanced activity of the oxidative branch of the PPP. This is expected to generate higher levels of NADPH, which, in turn, should contribute to improving ROS scavenging by maintaining glutathione in its reduced state. We thus determined ROS and glutathione levels in our cell model. Seven out of the 8 AMIECs contained ROS at significantly higher levels than control cells (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). The one cell line with near-normal ROS levels, CE-45, was the same one displayed normal levels of G6PD protein (<xref ref-type="fig" rid="fig4">Figure 4C and D</xref>). Similarly, the intracellular concentration of reduced glutathione was increased in all 8 AMIECs (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). These observations suggest that glutathione levels are upregulated in AMIECs to counter excess ROS levels.</p><p>In vivo, endothelial cells in AMI patients are under numerous physiological and pathological stresses, including mechanical and inflammatory, which may generate excess ROS and oxidative stress (<xref ref-type="bibr" rid="bib13">Dasgupta et al., 2018</xref>; <xref ref-type="bibr" rid="bib42">Seo and Lee, 2014</xref>). However, our patient-derived cells are no longer in an in vivo environment and are rather in an in vitro environment identical to that of control endothelial cells, and, therefore, their increased ROS levels cannot be directly attributed to environmental factors. Absent maintenance of long-term epigenetic memory of past stress responses in vivo, it is reasonable to assume that the high levels of ROS in AIM patient-derived cells may be elicited by endogenous damage signals impinging upon mitochondria (<xref ref-type="bibr" rid="bib36">Murphy, 2009</xref>) or through NAD(P)H oxidases.</p></sec><sec id="s2-5"><title>AMIECs exhibit a strong glutamine metabolism</title><p>Given the likely relevance of glutathione in the observed phenotypes and the possibility of a glutamine origin of the excess lactate produced in AMIECs, we assessed glutamate and cysteine contents in these cells. Determination of the extracellular fluxes of glutamine showed that the consumption of glutamine in AMIECs is higher than in control HCAECs (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). The latter consumed more glucose than patient-derived cells (see above), and thus the glutamine-to-glucose consumption ratio is far greater in patient-derived cells than in control cells (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). This suggests that AMI patient-derived cells mainly resort to glutamine, rather than glucose, as their carbon source.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>AMI-derived endothelial cells (AMIECs) display a strong glutamine metabolism.</title><p>(<bold>A</bold>) Glutamine and glucose production levels in cell culture medium after 48 hr. Negative values reflect net consumption. (<bold>B</bold>) Representative Western blotting experiments in AMIECs and human coronary artery endothelial cells (HCAECs) for the two major isoforms of GLS1, kidney-type glutaminase (KGA), and glutaminase C (GAC), using isoform-specific antibodies (<xref ref-type="supplementary-material" rid="fig5sdata1">Figure 5—source data 1</xref>). (<bold>C</bold>) Quantification of band intensities for KGA and GAC in triplicate western blotting experiments, normalized to β-actin band intensities. (<bold>D</bold>) Ratio of KGA vs. GAC isoform expression levels, calculated from the actin-normalized band intensities quantitated in (<bold>C</bold>). (<bold>E</bold>) Intracellular amino acid levels (<bold>F</bold>) Glutamate and glutamine production levels in cell culture medium after 48 hr. Negative values reflect net consumption. (<bold>G</bold>) Glutamine/glutamate consumption ratio. (<bold>H</bold>) Mitochondrial metabolic potential of AMIECs and control HCAEC cells. Cells were stained with 50 nM DiIC<sub>1</sub>(5) without or with 50 µM carbonyl cyanide 3-chlorophenylhydrazone (CCCP). Error bars represent mean ± SD (n=3). For all experiments, Student’s t-test significance values were calculated for AMIECs vs. HCAECs: *p≤0.05 **p≤0.01, and ***p≤0.001.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Western blotting experiments in AMIECs and HCAECs for the two major isoforms of GLS1, KGA and GAC.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-86260-fig5-data1-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-86260-fig5-v2.tif"/></fig><p>Glutamine is the most abundant free amino acid in circulation and in intracellular pools, and it is used by cells for both bioenergetics and biosynthetic needs; it can act as a carbon source or nitrogen donor and is consequently used as a precursor for the synthesis of amino acids, proteins, nucleotides and lipids, and represents the main substrate for TCA cycle anaplerosis (<xref ref-type="bibr" rid="bib15">DeBerardinis and Cheng, 2010</xref>; <xref ref-type="bibr" rid="bib17">Draoui et al., 2017</xref>; <xref ref-type="bibr" rid="bib21">Fitzgerald et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Laplante and Sabatini, 2012</xref>). Moreover, glutamine participates in redox homeostasis, a process that has a close connection with the PPP, as one of its main functions is to generate glutathione to counter the oxidative stress generated by ROS (see above). Thus, the increased glutamine consumption observed in AMIECs is consistent with the increased glutathione levels observed in these cells (<xref ref-type="fig" rid="fig4">Figure 4G</xref>).</p><p>The anaplerotic role of glutamine requires its conversion to glutamate, in a reaction catalyzed by glutaminase (GLS). There are three isoforms of human GLS: the kidney-type (KGA) and its splice variant glutaminase C (GAC) encoded by the GLS1 gene, and the liver-type (LGA) encoded by the GLS2 gene (<xref ref-type="bibr" rid="bib47">Thangavelu et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">van den Heuvel et al., 2012</xref>). Notably, the GAC isoform is crucial for cell growth under acidic pH, as would be expected in the presence of high levels of lactate (<xref ref-type="bibr" rid="bib1">Aguilar et al., 2016</xref>). Given the high levels of glutamine consumption observed in patient-derived cells, we determined the expression of glutaminase by Western blotting, using isoform-specific antibodies (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Consistently, both isoforms of GLS1, KGA, and GAC, are expressed at significantly higher levels in patient-derived cells than control cells (<xref ref-type="fig" rid="fig5">Figure 5B and C</xref>), with a higher KGA/GAC ratio in AMIECs (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>Next, polar intracellular metabolites (TCA cycle intermediates and amino acids) were determined by GC/MS. The results disclosed a higher intracellular content of all amino acids determined, with the exception of glycine, alanine, histidine, and proline. Among AMIECs, CE45 displayed the intracellular amino acid profile most resembling that of control HCAECs (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), consistent with the overall normal-like phenotype of this cell line. Cysteine and glutamate play important roles in the synthesis of glutathione (GSH) (<xref ref-type="bibr" rid="bib27">Ishimoto et al., 2011</xref>) and both had significantly higher concentrations in all AMIECs (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), consistent with higher levels of GSH as compared to control cells. Most of the glutamine transported into the cell is converted to glutamate by glutaminase, which is then converted to α-ketoglutarate (αKG) by glutamate dehydrogenase (GLDH). αKG is used as a carbon source for the anaplerotic replenishment of the TCA cycle, while glutamate, which normally accumulates in the cells, is a precursor of GSH. Thus, glutamate also contributes to redox homeostasis and ROS detoxification, along with the PPP. We thus determined glutamate levels in culture media, finding lower levels of production in 6 out of the 8 patient-derived cells as compared to control cells (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Moreover, the ratio between glutamate production and glutamine consumption was considerably lower in AMIECs (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). Because of the high levels of glutaminase in patient-derived cells, implying a strong conversion of glutamine to glutamate, the lower levels of extracellular export of glutamate are suggestive of a robust consumption of glutamate in the production of GSH in these cells.</p><p>Collectively, our data suggest that AMIECs rely heavily on glutamine, both as an alternative to glucose as a carbon source and in order to maintain redox homeostasis in these cells. Related to our observations, a link between glutamine metabolism and clinical manifestations of atherosclerosis, such as intima-media thickness and plaque development, has been described (<xref ref-type="bibr" rid="bib24">Grajeda-Iglesias and Aviram, 2018</xref>; <xref ref-type="bibr" rid="bib53">Wurtz et al., 2012</xref>).</p><p>These observations are consistent with higher levels of mitochondrial respiration and higher anaplerotic use of glutamate. The transport of glutamate into mitochondria is also essential for the biosynthesis of aspartate (<xref ref-type="bibr" rid="bib52">Wong et al., 2016</xref>). Consistently, aspartate was found at increased levels in AMIECs (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). Aspartate derived from oxaloacetate, via glutaminolysis, produces NAD+, required for glycolysis and NADPH, needed for redox balance. Aspartate derived from oxaloacetate, via glutaminolysis, produces NAD+, required for glycolysis and NADPH, needed for redox balance (<xref ref-type="bibr" rid="bib52">Wong et al., 2016</xref>). Therefore, this pathway also contributes to offset the high levels of ROS in these cells.</p><p>A possible source of the high levels of ROS observed in patient-derived cells is increased mitochondrial respiration in these cells. On the other hand, high levels of glutaminase and glutamine consumption suggest a strong activation of glutaminolysis in patient-derived cells. Once in the internal space of the mitochondria, glutamate is converted into α-ketoglutarate and ammonia by glutamate dehydrogenase, along with the reduction of NAD(P)<sup>+</sup> into NADPH. NADH is the substrate of complex I of the mitochondrial respiratory chain, and its oxidation results in the translocation of H<sup>+</sup> across the membrane, thus producing a proton gradient. Together, our evidence predicts an increased mitochondrial membrane potential in these cells. High membrane potential implies large negative potentials in the mitochondrial matrix, leading to glutamate expulsion and high glutaminase activity. Maintenance of the mitochondrial membrane potential (Δψm) is an essential component in the process of energy storage during oxidative phosphorylation, as it reflects the pumping of H<sup>+</sup> across the inner membrane during the process of electron transport and oxidative phosphorylation (<xref ref-type="bibr" rid="bib56">Zorova et al., 2018</xref>).</p><p>We thus determined the status of the mitochondrial membrane potential in our cells. For this, we used the fluorescent probe DiIC1(5) (MitoProbe), a positively charged, cell-permeant dye that accumulates within the negatively-charged mitochondrial matrix. MitoProbe accumulated at significantly higher levels in all AMIECs relative to control HCAECs (<xref ref-type="fig" rid="fig5">Figure 5H</xref>), indicating a mitochondrial hyperpolarization due to increased membrane potentials. The subsequent addition of the uncoupling agent carbonyl cyanide m-chlorophenylhydrazone (CCCP) resulted in rapid depolarization, reflecting the proton gradient dissipation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Understanding metabolic reprogramming as a paramount process driving the endothelial dysfunction that underlies atherogenic cardiovascular diseases is critical for designing new therapeutic approaches, in conjunction with conventional interventions, to tackle still unmet needs for better clinical management of these broad categories of disease. Much of the accrued evidence for metabolic and mitochondrial dysfunction in ECs in atherogenesis comes from animal models (<xref ref-type="bibr" rid="bib37">Negre-Salvayre et al., 2020</xref>) or studies in patients (<xref ref-type="bibr" rid="bib43">Shemiakova et al., 2020</xref>), critical scenarios to achieve a contextual understanding of the pathophysiological processes at stake.</p><p>In this study, we have departed from those approaches, in an attempt to better delineate cell-autonomous metabolic features of ECs derived from AMI patients, or AMIECs. We have found that contrary to physiologically normal ECs, which rely mostly on glycolysis for energy production rather than mitochondrial respiration (<xref ref-type="bibr" rid="bib29">Krützfeldt et al., 1990</xref>), AMIECs display low levels of glycolysis, as attested by low glucose consumption and downregulation of PFKFB3, which catalyzes the production of fructose-2,6-bisP (F2,6BP), a potent allosteric activator of the glycolysis rate-limiting enzyme 6-phosphofructokinase-1 (PFK-1), while also displaying a high membrane potential, suggestive of a high mitochondrial activity. Consistent with high levels of mitochondrial activity, AMIECs display a high intracellular content of ROS. The combination of high membrane potential and high ROS levels suggests robust proton coupling at the inner mitochondrial membrane, as uncoupling through the expression of UCP1 or the use of pharmacological uncouplers has been shown to mitigate ROS production (<xref ref-type="bibr" rid="bib10">Cadenas, 2018</xref>). We have found that the augmented ROS content is counteracted in AMIECs by an augmented intracellular content of glutathione, a physiological homeostatic mechanism to prevent damage from excess ROS (<xref ref-type="bibr" rid="bib26">Hayes et al., 2020</xref>). We also provide evidence that the major pathways enabling the biosynthesis of glutathione, the PPP and glutaminolysis, are overactivated in AIMECs as compared to control coronary ECs. The relatively low levels of expression of PFKFB3 and high levels of PFKFB4 point to a shunting of glycolysis towards the PPP in AMIECs, in order to produce NADPH.</p><p>Both PFKFB4 and PFKFB3 are upregulated in hypoxia through transcriptional activation by HIF-1α (<xref ref-type="bibr" rid="bib34">Minchenko et al., 2014</xref>), the mTOR pathway (<xref ref-type="bibr" rid="bib20">Feng and Wu, 2017</xref>), and peroxisome proliferator-activating receptor γ (PPARγ) (<xref ref-type="bibr" rid="bib44">Shu et al., 2016</xref>). On the other hand, although wild-type p53, activated in response to DNA damage, transcriptionally represses both PFKFB3 and PFKFB4, PFKFB4, but not PFKFB3, has been described as strongly upregulated in the absence of p53 (<xref ref-type="bibr" rid="bib40">Ros et al., 2017</xref>).</p><p>While, similar to HIF-1α, mTOR, and PPARγ drive glycolysis, our patient-derived endothelial cells show evidence of diminished glycolysis accompanied with low expression levels of PFKFB3, and thus it seems unlikely that the high levels of PFKFB4 observed in these cells are a downstream outcome of the activation of these pathways. The hypothesis of a blunted function of p53 as a driver of PFKFB4 upregulation in these cells could merit further investigation. Interestingly, the malic enzyme isoforms, ME1 and ME2, are also under negative regulation by p53 and are upregulated in the absence of p53 (<xref ref-type="bibr" rid="bib40">Ros et al., 2017</xref>). Regardless of the mechanisms underlying PFKFB3 low-expression along with PFKFB4 over-expression in AMIECs, predicted downstream consequences are (1) decreased levels of F-2,6-P2 resulting in low PFK1 activity and diminished glycolytic flux, which is consistent with the observed phenotypes, and (2) shunting of G6P towards the PPP, reinforced by the activation by PFKFB4 of steroid receptor coactivator-3 (SRC-3), enhancing its transcriptional activity and stimulating the expression of transketolase (TKT) (<xref ref-type="bibr" rid="bib13">Dasgupta et al., 2018</xref>).</p><p>The high levels of lactate production observed in AMIECs, concomitant with low glucose consumption, represent a conundrum. High lactate production is frequently linked to strong glycolytic activity, as the glycolytic end-product, pyruvate, can be converted to lactate catalyzed by the enzymatic activity of lactate dehydrogenase-A (LDH-A). Indeed, in highly proliferating cells, such as cancer or progenitor cells, a high rate of glycolysis can be accompanied by an inhibition of the mitochondrial entry of pyruvate, which, instead, is diverted towards the generation of lactate, a metabolic rewiring designated the Warburg effect, or aerobic glycolysis (<xref ref-type="bibr" rid="bib9">Burns and Manda, 2017</xref>). Strong glycolysis coupled with high lactate production and mitochondrial shutdown is also characteristic of hypoxia, through transcriptional regulation by HIF-1α of key regulators of these three processes, and has been observed in dysfunctional endothelial cells associated with atherosclerosis and vascular diseases (<xref ref-type="bibr" rid="bib21">Fitzgerald et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Theodorou and Boon, 2018</xref>).</p><p>In the LDH-A catalyzed reaction, pyruvate accepts electrons from NADH, yielding lactate and replenishing NAD<sup>+</sup>, predicted to be depleted in AMIECs by a strong drive to produce reducing equivalents and by the increased mitochondrial membrane potential, which impairs electron transport and NAD + regeneration (<xref ref-type="bibr" rid="bib33">Luengo et al., 2021</xref>). However, under conditions of low glucose consumption and evidence of low glycolytic activity, an alternative source is needed that may explain high lactate production from pyruvate in AMIECs. One possibility is through glutamine-initiated metabolism (<xref ref-type="bibr" rid="bib55">Zielke et al., 1980</xref>), which would be consistent with the strong glutamine consumption observed in AMIECs. In this regard, it has been shown in pancreatic cancer cells that glutamine-derived pyruvate plays a significant role in redox homeostasis.</p><p>Collectively, our observations and evidence by others suggest the occurrence of two cell-autonomous, primary deficiencies in AMI patient-derived ECs, namely (1) a strong proton coupling in the mitochondrial membrane that results in excess ROS production, countered by enhanced NADPH and glutathione levels, driven by a glycolysis-to-PPP shunt and an enhanced glutamine metabolism; and (2) a switch in carbon source preference from glucose to glutamine, possibly as an adaptive mechanism aimed at potentiating the production of glutathione, while employing alternative pyruvate-to-lactate conversion pathways that replenish NAD+, thus maintaining a viable redox homeostasis (<xref ref-type="bibr" rid="bib28">Kerk et al., 2022</xref>).</p><p>Primary dysfunctions in mitochondria, from either inherited or acquired genetic defects, have been suggested as underlying causes of atherogenic pathologies (<xref ref-type="bibr" rid="bib12">Dabravolski et al., 2022</xref>). Alternatively, our AIMECs might continue to carry, ex-vivo, epigenetic imprints of their exposure to factors and cells while in the patients, which could determine altered phenotypes through many cellular generations. Independent of the original insult, a possible intervention to revert the observed mitochondrial dysfunction would be the use of pharmacological uncouplers to mitigate ROS production and the accompanying metabolic reprogramming (<xref ref-type="bibr" rid="bib10">Cadenas, 2018</xref>). Relevantly, knockout of the uncoupling protein UCP1 caused vascular dysfunction, atherogenesis, and NLRP3 inflammasome activation and IL1-β-dependent inflammation, relieved by re-expression of UCP1 or treatment of animals with chemical uncouplers (<xref ref-type="bibr" rid="bib25">Gu et al., 2021</xref>).</p></sec><sec id="s4" sec-type="methods"><title>Methods</title><sec id="s4-1"><title>Endothelial cells</title><p>AMIECs were isolated from coronary atherothrombotic specimens in patients undergoing percutaneous coronary intervention with thrombectomy for the treatment of acute STEMI at the Royal Infirmary of Edinburgh, Scotland, UK. Relevant clinical features of the patients are summarized in <xref ref-type="table" rid="table1">Table 1</xref>. The study protocol was approved by the Institutional Research Ethics Committee, and all subjects provided written informed consent. Specimens were washed with phosphate-buffered saline (PBS) and manually disaggregated. Tissue explants were seeded onto collagen-I coated six-well plates and maintained under standard cell culture conditions. After 24 hr, tissue explants, non-adherent cells, and debris were aspirated. The medium was changed every other day until the first passage of coronary endothelial outgrowth cells emerged and cells were cultured as described (<xref ref-type="bibr" rid="bib7">Brittan et al., 2015</xref>; <xref ref-type="bibr" rid="bib38">Padfield et al., 2013</xref>; <xref ref-type="bibr" rid="bib50">Tura et al., 2013</xref>), on 0.2% gelatin-coated plates with EGM-2 BulletKit medium (Lonza, Basel, Switzerland), containing EBM-2 basal medium along with the EGM-2 SingleQuots kit components, 10% fetal bovine serum (FBS) and penicillin-streptomycin. Human coronary artery endothelial cells (HCAECs) were purchased from Lonza Clonetics (Walkersville, USA) and used as controls. All cell cultures were maintained in a 37 °C humidified incubator at 5% CO2.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Clinical characteristics of patients providing coronary endothelial outgrowth following thrombectomy for ST-segment elevation myocardial infarction.</title><p>Values are number (%) or mean ± standard deviation. ACE = angiotensin-converting enzyme; CABG = coronary artery bypass grafting; PCI = percutaneous coronary intervention.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">n=<bold><italic>8</italic></bold></th></tr></thead><tbody><tr><td align="left" valign="bottom">Age, years</td><td align="left" valign="bottom">60±15</td></tr><tr><td align="left" valign="bottom">Gender, male</td><td align="left" valign="bottom">5 (66%)</td></tr><tr><th align="left" valign="bottom" colspan="2">Medical history and risk factors</th></tr><tr><td align="left" valign="bottom">Previous myocardial infarction</td><td align="left" valign="bottom">1 (12%)</td></tr><tr><td align="left" valign="bottom">Previous PCI/CABG</td><td align="left" valign="bottom">1 (12 %)</td></tr><tr><td align="left" valign="bottom">Current smoker</td><td align="left" valign="bottom">3 (37%)</td></tr><tr><td align="left" valign="bottom">Ex-smoker</td><td align="left" valign="bottom">2 (25%)</td></tr><tr><td align="left" valign="bottom">Hypertension</td><td align="left" valign="bottom">1 (12%)</td></tr><tr><td align="left" valign="bottom">Hyperlipidaemia</td><td align="left" valign="bottom">4 (50%)</td></tr><tr><td align="left" valign="bottom">Family history of premature coronary heart disease</td><td align="left" valign="bottom">1 (12%)</td></tr><tr><td align="left" valign="bottom">Diabetes mellitus</td><td align="left" valign="bottom">0</td></tr><tr><th align="left" valign="bottom" colspan="2">Medication on admission</th></tr><tr><td align="left" valign="bottom">Aspirin</td><td align="left" valign="bottom">2 (25%)</td></tr><tr><td align="left" valign="bottom">Clopidogrel</td><td align="left" valign="bottom">1 (12%)</td></tr><tr><td align="left" valign="bottom">B-Blockers</td><td align="left" valign="bottom">1 (12%)</td></tr><tr><td align="left" valign="bottom">ACE-Inhibitors</td><td align="left" valign="bottom">1 (12%)</td></tr><tr><td align="left" valign="bottom">Statins</td><td align="left" valign="bottom">3 (38%)</td></tr><tr><th align="left" valign="bottom" colspan="2">Myocardial injury</th></tr><tr><td align="left" valign="bottom">Troponin I concentration, micrograms/L</td><td align="left" valign="bottom">27.9±20.0</td></tr><tr><th align="left" valign="bottom" colspan="2">Culprit vessel</th></tr><tr><td align="left" valign="bottom">Left anterior descending artery, n=12</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Circumflex artery, n=2</td><td align="left" valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Right coronary artery, n=23</td><td align="left" valign="bottom">4</td></tr></tbody></table></table-wrap></sec><sec id="s4-2"><title>Cell proliferation and viability assays</title><p>Cells were counted either with a Scepter Handheld Automated Cell Counter (Merck Millipore, Billerica, MA, USA) or by Hoechst nuclear staining (HO33342, Sigma-Aldrich) (<xref ref-type="bibr" rid="bib1">Aguilar et al., 2016</xref>).</p></sec><sec id="s4-3"><title>In vitro migration (wound healing) assay</title><p>Cells were cultured on 12-well plates in a complete medium supplemented with 10% FBS and antibiotics. After reaching confluence, cells were starved for 1 hr in a medium containing 0.5% FBS and mitomycin C (1 mg/mL), a cytostatic drug that reacts covalently with DNA forming crosslinks between the complementary strands of DNA, preventing the separation of the complementary DNA strands and inhibiting DNA replication.</p></sec><sec id="s4-4"><title>Tubulogenesis assay</title><p>Endothelial tube formation was monitored using an in vitro angiogenesis assay kit (Merck Millipore ECM625) following the manufacturer’s instructions. Briefly, EC cells were cultured in 96 wells plates coated with 5% Matrigel (growth factor-free, Corning # 354230) in EGM2 medium without FBS and supplemented with 1% non-essential amino-acids and antibiotics and left in the incubator for 12 hr. Tube branching points were scored in 5 random fields per concentration using the Angiogenesis plug-in of the Image J software.</p></sec><sec id="s4-5"><title>Western blotting</title><p>70–80% confluent cells were harvested by trypsinization, washed 2 x with cold PBS, pellets resuspended in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 1% Triton X-100 and 0.5% sodium deoxycholate) supplemented with protease inhibitor cocktail (Sigma-Aldrich) and incubated on ice for 5–10 min. Equal amounts of protein per sample were electrophoresed on 8% or 12% SDS-PAGE and subjected to Western blotting.</p></sec><sec id="s4-6"><title>Quantification of metabolites</title><p>Glucose, lactate, glutamate, and glutamine were determined by spectrophotometry (COBAS Mira Plus, Horiba ABX) from cell culture media by monitoring the production of NAD(P)H in specific reactions for each metabolite at 340 nm.</p></sec><sec id="s4-7"><title>Analysis of polar intracellular metabolites (TCA cycle intermediates and amino acids)</title><p>Cells were grown to 70–80% confluence at the required condition for each cellular model and then media were removed, and plates were washed with ice-cold PBS. TCA cycle intermediates were extracted with the addition of 100% methanol:H<sub>2</sub>O (1:1) mixture and scrapping on ice; then, the extracts were sonicated using a titanium probe (VibraCell, Sonics &amp; Materials Inc, three cycles of 5 s), chloroform added to the lysates and tubes placed in a shaker for vigorous agitation at 4 °C for 30 min. Subsequently, samples were centrifuged and the upper aqueous phase was separated and evaporated under airflow at room temperature, adding dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>) for complete dehydration of the samples. TCA cycle intermediates were derivatized by adding 2% (v/v) methoxyamine hydrochloride in pyridine and shaken vigorously at 37 °C for 90 min. Next, N-methyl-N- (tert-butyldimethylsilyl) trifluoroacetamide (MBTSTFA) and 1% tertbutyldimetheylchlorosilane (TBDMCS) were added, samples incubated for 1 hr at 55 °C and finally transferred to GC/MS vials. GC/MS analysis was performed under an electron impact ionization model (<xref ref-type="bibr" rid="bib11">Cascante and Marin, 2008</xref>; <xref ref-type="bibr" rid="bib16">Dettmer et al., 2007</xref>). The relative concentration of the polar intracellular metabolites is quantified using Norvaline (1 mg/mL) as an internal standard.</p></sec><sec id="s4-8"><title>Glucose-6-phosphate dehydrogenase activity</title><p>Cell extracts were prepared using lysis buffer 20 mM Tris-HCl, supplemented with 1 mM DTT, 1 mM EDTA, 0.02% (v/v) Triton X-100, 0.02% (v/v) sodium deoxycholate and protease inhibition cocktail (Sigma-Aldrich). Lysates were sonicated (VibraCell, Sonics &amp; Materials Inc) and centrifuged at 12,000 × g for 20 min at 4 °C. G6PDH specific activity was measured by adding samples to a cuvette containing 0.5 mM NADP<sup>+</sup> in 50 mM Tris-HCl, pH 7.6, at 37 °C. The reaction was initiated by the addition of glucose-6-phosphate at a final concentration of 2 mM (<xref ref-type="bibr" rid="bib1">Aguilar et al., 2016</xref>).</p></sec><sec id="s4-9"><title>Intracellular ROS determination</title><p>Total intracellular ROS levels were determined by means of flow cytometry using the H2DCFDA probe (Invitrogen). Cells were incubated with incubation buffer 5.5 mM glucose in PBS containing 5 µM H<sub>2</sub>DCFDA for 30 min at 37 °C and 5% CO<sub>2</sub>.</p></sec><sec id="s4-10"><title>GSH/GSSG quantification</title><p>Fresh cells were lysed with 5% 5-sulfosalicylic acid (Sigma-Aldrich) solution, vortexed, and disrupted by two freeze/thaw cycles in liquid N<sub>2</sub> and 37 °C water bath. Fifty µL of this solution was separated for subsequent protein quantification. Cell extracts were kept at 4 °C for 10 min and centrifuged at 10,000 × g for 10 min. For glutathione quantification, 15 U/mL of glutathione reductase and 40 µg/mL of 5,5’-dithiobis(2-nitrobenzoic acid) (Sigma-Aldrich) were dissolved in assay buffer (100 mM K<sub>2</sub>HPO<sub>4</sub>/KH<sub>2</sub>PO<sub>4</sub>, 1 mM EDTA, pH 7.0).</p></sec><sec id="s4-11"><title>Mitochondrial membrane potential</title><p>Cells were incubated with MitoProbe DiIC1(5) (1,1′,3,3,3′,3′-hexamethylindodicarbo -cyanine iodide) with or without CCCP (carbonyl cyanide 3-chlorophenylhydrazone) as a mitochondrial membrane potential disruptor, and scored by flow cytometry.</p><p>Detailed protocols are available upon request.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Resources, Funding acquisition, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Acute myocardial infection patient-derived endothelial cells (AMIECs) were isolated from coronary atherothrombotic specimens in patients undergoing percutaneous coronary intervention with thrombectomy for the treatment of acute ST-segment elevation myocardial infarction (STEMI) at the Royal Infirmary of Edinburgh, Scotland, UK. The study protocol was approved by the Institutional Research Ethics Committee, and all subjects provided written informed consent.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-86260-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="repstand1"><label>Reporting standard 1.</label><media xlink:href="elife-86260-repstand1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript.</p></sec><ack id="ack"><title>Acknowledgements</title><p>The project leading to this work has received funding from: The European Commission Horizon 2020 research and innovation program under the MOGLYNET H2020-MSCA-ITN-EJD grant (agreement No 675527); CIBER- Carlos III National Institute of Health, Spain (TT and MCas: CIBEREHD-CB17/04/00023; OTC: CIBERES-CP17/00114); Spanish Ministerio de Economia y Competitividad (MINECO) and Ministerio de Ciencia e Innovación -European Commission FEDER funds—'Una manera de hacer Europa' (TT: PID2019-107139RB-C21 and MCas: PID2020-115051RB-I00); Generalitat de Catalunya-AGAUR (MCas: ICREA Academia Prize 2021, MCas: 2021 SGR00350; TT: 2021 SGR1490); Plataforma Temática Interdisciplinary – Salud Global (TT: SGL2103019); NLM is supported by the British Heart Foundation (RE/18/5/34216, RG/20/10/34966, CH/F/21/90010).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>E</given-names></name><name><surname>Marin de Mas</surname><given-names>I</given-names></name><name><surname>Zodda</surname><given-names>E</given-names></name><name><surname>Marin</surname><given-names>S</given-names></name><name><surname>Morrish</surname><given-names>F</given-names></name><name><surname>Selivanov</surname><given-names>V</given-names></name><name><surname>Meca-Cortés</surname><given-names>Ó</given-names></name><name><surname>Delowar</surname><given-names>H</given-names></name><name><surname>Pons</surname><given-names>M</given-names></name><name><surname>Izquierdo</surname><given-names>I</given-names></name><name><surname>Celià-Terrassa</surname><given-names>T</given-names></name><name><surname>de Atauri</surname><given-names>P</given-names></name><name><surname>Centelles</surname><given-names>JJ</given-names></name><name><surname>Hockenbery</surname><given-names>D</given-names></name><name><surname>Thomson</surname><given-names>TM</given-names></name><name><surname>Cascante</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Metabolic reprogramming and dependencies associated with epithelial cancer stem cells independent of the epithelial-mesenchymal transition program</article-title><source>Stem Cells</source><volume>34</volume><fpage>1163</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1002/stem.2286</pub-id><pub-id pub-id-type="pmid">27146024</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badimon</surname><given-names>L</given-names></name><name><surname>Padró</surname><given-names>T</given-names></name><name><surname>Vilahur</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease</article-title><source>European Heart Journal. Acute Cardiovascular Care</source><volume>1</volume><fpage>60</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1177/2048872612441582</pub-id><pub-id pub-id-type="pmid">24062891</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benito</surname><given-names>A</given-names></name><name><surname>Polat</surname><given-names>IH</given-names></name><name><surname>Noé</surname><given-names>V</given-names></name><name><surname>Ciudad</surname><given-names>CJ</given-names></name><name><surname>Marin</surname><given-names>S</given-names></name><name><surname>Cascante</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Glucose-6-phosphate dehydrogenase and transketolase modulate breast cancer cell metabolic reprogramming and correlate with poor patient outcome</article-title><source>Oncotarget</source><volume>8</volume><fpage>106693</fpage><lpage>106706</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.21601</pub-id><pub-id pub-id-type="pmid">29290982</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bensaad</surname><given-names>K</given-names></name><name><surname>Tsuruta</surname><given-names>A</given-names></name><name><surname>Selak</surname><given-names>MA</given-names></name><name><surname>Vidal</surname><given-names>MNC</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Bartrons</surname><given-names>R</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><name><surname>Vousden</surname><given-names>KH</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>TIGAR, a p53-inducible regulator of glycolysis and apoptosis</article-title><source>Cell</source><volume>126</volume><fpage>107</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.05.036</pub-id><pub-id pub-id-type="pmid">16839880</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bester</surname><given-names>AC</given-names></name><name><surname>Roniger</surname><given-names>M</given-names></name><name><surname>Oren</surname><given-names>YS</given-names></name><name><surname>Im</surname><given-names>MM</given-names></name><name><surname>Sarni</surname><given-names>D</given-names></name><name><surname>Chaoat</surname><given-names>M</given-names></name><name><surname>Bensimon</surname><given-names>A</given-names></name><name><surname>Zamir</surname><given-names>G</given-names></name><name><surname>Shewach</surname><given-names>DS</given-names></name><name><surname>Kerem</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Nucleotide deficiency promotes genomic instability in early stages of cancer development</article-title><source>Cell</source><volume>145</volume><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.03.044</pub-id><pub-id pub-id-type="pmid">21529715</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Botts</surname><given-names>SR</given-names></name><name><surname>Fish</surname><given-names>JE</given-names></name><name><surname>Howe</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dysfunctional vascular endothelium as a driver of atherosclerosis: emerging insights into pathogenesis and treatment</article-title><source>Frontiers in Pharmacology</source><volume>12</volume><elocation-id>787541</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2021.787541</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brittan</surname><given-names>M</given-names></name><name><surname>Hunter</surname><given-names>A</given-names></name><name><surname>Boulberdaa</surname><given-names>M</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Skinner</surname><given-names>EM</given-names></name><name><surname>Shah</surname><given-names>AS</given-names></name><name><surname>Baker</surname><given-names>AH</given-names></name><name><surname>Mills</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Impaired vascular function and repair in patients with premature coronary artery disease</article-title><source>European Journal of Preventive Cardiology</source><volume>22</volume><fpage>1557</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1177/2047487315600169</pub-id><pub-id pub-id-type="pmid">26276790</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The science and translation of lactate shuttle theory</article-title><source>Cell Metabolism</source><volume>27</volume><fpage>757</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2018.03.008</pub-id><pub-id pub-id-type="pmid">29617642</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burns</surname><given-names>JS</given-names></name><name><surname>Manda</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic pathways of the warburg effect in health and disease: perspectives of choice, chain or chance</article-title><source>International Journal of Molecular Sciences</source><volume>18</volume><elocation-id>2755</elocation-id><pub-id pub-id-type="doi">10.3390/ijms18122755</pub-id><pub-id pub-id-type="pmid">29257069</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cadenas</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondrial uncoupling, ROS generation and cardioprotection</article-title><source>Biochimica et Biophysica Acta. Bioenergetics</source><volume>1859</volume><fpage>940</fpage><lpage>950</lpage><pub-id pub-id-type="doi">10.1016/j.bbabio.2018.05.019</pub-id><pub-id pub-id-type="pmid">29859845</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cascante</surname><given-names>M</given-names></name><name><surname>Marin</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Metabolomics and fluxomics approaches</article-title><source>Essays in Biochemistry</source><volume>45</volume><fpage>67</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1042/BSE0450067</pub-id><pub-id pub-id-type="pmid">18793124</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dabravolski</surname><given-names>SA</given-names></name><name><surname>Nikiforov</surname><given-names>NG</given-names></name><name><surname>Zhuravlev</surname><given-names>AD</given-names></name><name><surname>Orekhov</surname><given-names>NA</given-names></name><name><surname>Grechko</surname><given-names>AV</given-names></name><name><surname>Orekhov</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Role of the mtDNA mutations and mitophagy in inflammaging</article-title><source>International Journal of Molecular Sciences</source><volume>23</volume><elocation-id>1323</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23031323</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>S</given-names></name><name><surname>Rajapakshe</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Nikolai</surname><given-names>BC</given-names></name><name><surname>Yi</surname><given-names>P</given-names></name><name><surname>Putluri</surname><given-names>N</given-names></name><name><surname>Choi</surname><given-names>JM</given-names></name><name><surname>Jung</surname><given-names>SY</given-names></name><name><surname>Coarfa</surname><given-names>C</given-names></name><name><surname>Westbrook</surname><given-names>TF</given-names></name><name><surname>Zhang</surname><given-names>XH-F</given-names></name><name><surname>Foulds</surname><given-names>CE</given-names></name><name><surname>Tsai</surname><given-names>SY</given-names></name><name><surname>Tsai</surname><given-names>M-J</given-names></name><name><surname>O’Malley</surname><given-names>BW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer</article-title><source>Nature</source><volume>556</volume><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0018-1</pub-id><pub-id pub-id-type="pmid">29615789</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Bock</surname><given-names>K</given-names></name><name><surname>Georgiadou</surname><given-names>M</given-names></name><name><surname>Schoors</surname><given-names>S</given-names></name><name><surname>Kuchnio</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>BW</given-names></name><name><surname>Cantelmo</surname><given-names>AR</given-names></name><name><surname>Quaegebeur</surname><given-names>A</given-names></name><name><surname>Ghesquière</surname><given-names>B</given-names></name><name><surname>Cauwenberghs</surname><given-names>S</given-names></name><name><surname>Eelen</surname><given-names>G</given-names></name><name><surname>Phng</surname><given-names>L-K</given-names></name><name><surname>Betz</surname><given-names>I</given-names></name><name><surname>Tembuyser</surname><given-names>B</given-names></name><name><surname>Brepoels</surname><given-names>K</given-names></name><name><surname>Welti</surname><given-names>J</given-names></name><name><surname>Geudens</surname><given-names>I</given-names></name><name><surname>Segura</surname><given-names>I</given-names></name><name><surname>Cruys</surname><given-names>B</given-names></name><name><surname>Bifari</surname><given-names>F</given-names></name><name><surname>Decimo</surname><given-names>I</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Wyns</surname><given-names>S</given-names></name><name><surname>Vangindertael</surname><given-names>J</given-names></name><name><surname>Rocha</surname><given-names>S</given-names></name><name><surname>Collins</surname><given-names>RT</given-names></name><name><surname>Munck</surname><given-names>S</given-names></name><name><surname>Daelemans</surname><given-names>D</given-names></name><name><surname>Imamura</surname><given-names>H</given-names></name><name><surname>Devlieger</surname><given-names>R</given-names></name><name><surname>Rider</surname><given-names>M</given-names></name><name><surname>Van Veldhoven</surname><given-names>PP</given-names></name><name><surname>Schuit</surname><given-names>F</given-names></name><name><surname>Bartrons</surname><given-names>R</given-names></name><name><surname>Hofkens</surname><given-names>J</given-names></name><name><surname>Fraisl</surname><given-names>P</given-names></name><name><surname>Telang</surname><given-names>S</given-names></name><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Schoonjans</surname><given-names>L</given-names></name><name><surname>Vinckier</surname><given-names>S</given-names></name><name><surname>Chesney</surname><given-names>J</given-names></name><name><surname>Gerhardt</surname><given-names>H</given-names></name><name><surname>Dewerchin</surname><given-names>M</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Role of PFKFB3-driven glycolysis in vessel sprouting</article-title><source>Cell</source><volume>154</volume><fpage>651</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.06.037</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeBerardinis</surname><given-names>RJ</given-names></name><name><surname>Cheng</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer</article-title><source>Oncogene</source><volume>29</volume><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1038/onc.2009.358</pub-id><pub-id pub-id-type="pmid">19881548</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dettmer</surname><given-names>K</given-names></name><name><surname>Aronov</surname><given-names>PA</given-names></name><name><surname>Hammock</surname><given-names>BD</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Mass spectrometry-based metabolomics</article-title><source>Mass Spectrometry Reviews</source><volume>26</volume><fpage>51</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1002/mas.20108</pub-id><pub-id pub-id-type="pmid">16921475</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draoui</surname><given-names>N</given-names></name><name><surname>de Zeeuw</surname><given-names>P</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Angiogenesis revisited from a metabolic perspective: role and therapeutic implications of endothelial cell metabolism</article-title><source>Open Biology</source><volume>7</volume><elocation-id>170219</elocation-id><pub-id pub-id-type="doi">10.1098/rsob.170219</pub-id><pub-id pub-id-type="pmid">29263247</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dromparis</surname><given-names>P</given-names></name><name><surname>Michelakis</surname><given-names>ED</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mitochondria in vascular health and disease</article-title><source>Annual Review of Physiology</source><volume>75</volume><fpage>95</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-030212-183804</pub-id><pub-id pub-id-type="pmid">23157555</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eelen</surname><given-names>G</given-names></name><name><surname>de Zeeuw</surname><given-names>P</given-names></name><name><surname>Treps</surname><given-names>L</given-names></name><name><surname>Harjes</surname><given-names>U</given-names></name><name><surname>Wong</surname><given-names>BW</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Endothelial cell metabolism</article-title><source>Physiological Reviews</source><volume>98</volume><fpage>3</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1152/physrev.00001.2017</pub-id><pub-id pub-id-type="pmid">29167330</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival</article-title><source>Biochemical and Biophysical Research Communications</source><volume>483</volume><fpage>897</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2017.01.031</pub-id><pub-id pub-id-type="pmid">28082200</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>G</given-names></name><name><surname>Soro-Arnaiz</surname><given-names>I</given-names></name><name><surname>De Bock</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The warburg effect in endothelial cells and its potential as an anti-angiogenic target in cancer</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>6</volume><elocation-id>100</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2018.00100</pub-id><pub-id pub-id-type="pmid">30255018</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallogly</surname><given-names>S</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Hung</surname><given-names>JD</given-names></name><name><surname>Brittan</surname><given-names>M</given-names></name><name><surname>Skinner</surname><given-names>EM</given-names></name><name><surname>Mitchell</surname><given-names>AJ</given-names></name><name><surname>Medine</surname><given-names>C</given-names></name><name><surname>Luque</surname><given-names>N</given-names></name><name><surname>Zodda</surname><given-names>E</given-names></name><name><surname>Cascante</surname><given-names>M</given-names></name><name><surname>Hadoke</surname><given-names>PW</given-names></name><name><surname>Mills</surname><given-names>NL</given-names></name><name><surname>Tura-Ceide</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Generation of a novel in vitro model to study endothelial dysfunction from atherothrombotic specimens</article-title><source>Cardiovascular Drugs and Therapy</source><volume>35</volume><fpage>1281</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1007/s10557-021-07151-9</pub-id><pub-id pub-id-type="pmid">33608862</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goveia</surname><given-names>J</given-names></name><name><surname>Stapor</surname><given-names>P</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease</article-title><source>EMBO Molecular Medicine</source><volume>6</volume><fpage>1105</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.15252/emmm.201404156</pub-id><pub-id pub-id-type="pmid">25063693</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grajeda-Iglesias</surname><given-names>C</given-names></name><name><surname>Aviram</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Specific amino acids affect cardiovascular diseases and atherogenesis via protection against macrophage foam cell formation: review article</article-title><source>Rambam Maimonides Medical Journal</source><volume>9</volume><elocation-id>e0022</elocation-id><pub-id pub-id-type="doi">10.5041/RMMJ.10337</pub-id><pub-id pub-id-type="pmid">29944113</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>P</given-names></name><name><surname>Hui</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Nie</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mitochondrial uncoupling protein 1 antagonizes atherosclerosis by blocking NLRP3 inflammasome-dependent interleukin-1β production</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabl4024</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abl4024</pub-id><pub-id pub-id-type="pmid">34878840</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayes</surname><given-names>JD</given-names></name><name><surname>Dinkova-Kostova</surname><given-names>AT</given-names></name><name><surname>Tew</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Oxidative stress in cancer</article-title><source>Cancer Cell</source><volume>38</volume><fpage>167</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2020.06.001</pub-id><pub-id pub-id-type="pmid">32649885</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimoto</surname><given-names>T</given-names></name><name><surname>Nagano</surname><given-names>O</given-names></name><name><surname>Yae</surname><given-names>T</given-names></name><name><surname>Tamada</surname><given-names>M</given-names></name><name><surname>Motohara</surname><given-names>T</given-names></name><name><surname>Oshima</surname><given-names>H</given-names></name><name><surname>Oshima</surname><given-names>M</given-names></name><name><surname>Ikeda</surname><given-names>T</given-names></name><name><surname>Asaba</surname><given-names>R</given-names></name><name><surname>Yagi</surname><given-names>H</given-names></name><name><surname>Masuko</surname><given-names>T</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>T</given-names></name><name><surname>Kai</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>E</given-names></name><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Baba</surname><given-names>Y</given-names></name><name><surname>Ohmura</surname><given-names>M</given-names></name><name><surname>Suematsu</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>H</given-names></name><name><surname>Saya</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth</article-title><source>Cancer Cell</source><volume>19</volume><fpage>387</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2011.01.038</pub-id><pub-id pub-id-type="pmid">21397861</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerk</surname><given-names>SA</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Myers</surname><given-names>AL</given-names></name><name><surname>Sutton</surname><given-names>DJ</given-names></name><name><surname>Andren</surname><given-names>A</given-names></name><name><surname>Sajjakulnukit</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Jiménez</surname><given-names>JA</given-names></name><name><surname>Nelson</surname><given-names>BS</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Robinson</surname><given-names>A</given-names></name><name><surname>Thurston</surname><given-names>G</given-names></name><name><surname>Kemp</surname><given-names>SB</given-names></name><name><surname>Steele</surname><given-names>NG</given-names></name><name><surname>Hoffman</surname><given-names>MT</given-names></name><name><surname>Wen</surname><given-names>H-J</given-names></name><name><surname>Long</surname><given-names>D</given-names></name><name><surname>Ackenhusen</surname><given-names>SE</given-names></name><name><surname>Ramos</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Nwosu</surname><given-names>ZC</given-names></name><name><surname>Galban</surname><given-names>S</given-names></name><name><surname>Halbrook</surname><given-names>CJ</given-names></name><name><surname>Lombard</surname><given-names>DB</given-names></name><name><surname>Piwnica-Worms</surname><given-names>DR</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Pasca di Magliano</surname><given-names>M</given-names></name><name><surname>Crawford</surname><given-names>HC</given-names></name><name><surname>Shah</surname><given-names>YM</given-names></name><name><surname>Lyssiotis</surname><given-names>CA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context</article-title><source>eLife</source><volume>11</volume><elocation-id>e73245</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.73245</pub-id><pub-id pub-id-type="pmid">35815941</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krützfeldt</surname><given-names>A</given-names></name><name><surname>Spahr</surname><given-names>R</given-names></name><name><surname>Mertens</surname><given-names>S</given-names></name><name><surname>Siegmund</surname><given-names>B</given-names></name><name><surname>Piper</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Metabolism of exogenous substrates by coronary endothelial cells in culture</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>22</volume><fpage>1393</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.1016/0022-2828(90)90984-a</pub-id><pub-id pub-id-type="pmid">2089157</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laplante</surname><given-names>M</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>mTOR signaling in growth control and disease</article-title><source>Cell</source><volume>149</volume><fpage>274</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.03.017</pub-id><pub-id pub-id-type="pmid">22500797</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Horke</surname><given-names>S</given-names></name><name><surname>Förstermann</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Vascular oxidative stress, nitric oxide and atherosclerosis</article-title><source>Atherosclerosis</source><volume>237</volume><fpage>208</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.09.001</pub-id><pub-id pub-id-type="pmid">25244505</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Metabolic pathways fueling the endothelial cell drive</article-title><source>Annual Review of Physiology</source><volume>81</volume><fpage>483</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-020518-114731</pub-id><pub-id pub-id-type="pmid">30742787</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luengo</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Gui</surname><given-names>DY</given-names></name><name><surname>Sullivan</surname><given-names>LB</given-names></name><name><surname>Zagorulya</surname><given-names>M</given-names></name><name><surname>Do</surname><given-names>BT</given-names></name><name><surname>Ferreira</surname><given-names>R</given-names></name><name><surname>Naamati</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>CA</given-names></name><name><surname>Thomas</surname><given-names>CJ</given-names></name><name><surname>Spranger</surname><given-names>S</given-names></name><name><surname>Matheson</surname><given-names>NJ</given-names></name><name><surname>Vander Heiden</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Increased demand for NAD+ relative to ATP drives aerobic glycolysis</article-title><source>Molecular Cell</source><volume>81</volume><fpage>691</fpage><lpage>707</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.12.012</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minchenko</surname><given-names>OH</given-names></name><name><surname>Tsuchihara</surname><given-names>K</given-names></name><name><surname>Minchenko</surname><given-names>DO</given-names></name><name><surname>Bikfalvi</surname><given-names>A</given-names></name><name><surname>Esumi</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells</article-title><source>World Journal of Gastroenterology</source><volume>20</volume><fpage>13705</fpage><lpage>13717</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i38.13705</pub-id><pub-id pub-id-type="pmid">25320508</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreno-Viedma</surname><given-names>V</given-names></name><name><surname>Amor</surname><given-names>M</given-names></name><name><surname>Sarabi</surname><given-names>A</given-names></name><name><surname>Bilban</surname><given-names>M</given-names></name><name><surname>Staffler</surname><given-names>G</given-names></name><name><surname>Zeyda</surname><given-names>M</given-names></name><name><surname>Stulnig</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Common dysregulated pathways in obese adipose tissue and atherosclerosis</article-title><source>Cardiovascular Diabetology</source><volume>15</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.1186/s12933-016-0441-2</pub-id><pub-id pub-id-type="pmid">27561966</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>MP</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>How mitochondria produce reactive oxygen species</article-title><source>The Biochemical Journal</source><volume>417</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1042/BJ20081386</pub-id><pub-id pub-id-type="pmid">19061483</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Negre-Salvayre</surname><given-names>A</given-names></name><name><surname>Guerby</surname><given-names>P</given-names></name><name><surname>Gayral</surname><given-names>S</given-names></name><name><surname>Laffargue</surname><given-names>M</given-names></name><name><surname>Salvayre</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Role of reactive oxygen species in atherosclerosis: Lessons from murine genetic models</article-title><source>Free Radical Biology &amp; Medicine</source><volume>149</volume><fpage>8</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2019.10.011</pub-id><pub-id pub-id-type="pmid">31669759</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padfield</surname><given-names>GJ</given-names></name><name><surname>Tura-Ceide</surname><given-names>O</given-names></name><name><surname>Freyer</surname><given-names>E</given-names></name><name><surname>Barclay</surname><given-names>GR</given-names></name><name><surname>Turner</surname><given-names>M</given-names></name><name><surname>Newby</surname><given-names>DE</given-names></name><name><surname>Mills</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Endothelial progenitor cells, atheroma burden and clinical outcome in patients with coronary artery disease</article-title><source>Heart</source><volume>99</volume><fpage>791</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1136/heartjnl-2012-302949</pub-id><pub-id pub-id-type="pmid">23390050</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Previtali</surname><given-names>E</given-names></name><name><surname>Bucciarelli</surname><given-names>P</given-names></name><name><surname>Passamonti</surname><given-names>SM</given-names></name><name><surname>Martinelli</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Risk factors for venous and arterial thrombosis</article-title><source>Blood Transfusion = Trasfusione Del Sangue</source><volume>9</volume><fpage>120</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.2450/2010.0066-10</pub-id><pub-id pub-id-type="pmid">21084000</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ros</surname><given-names>S</given-names></name><name><surname>Flöter</surname><given-names>J</given-names></name><name><surname>Kaymak</surname><given-names>I</given-names></name><name><surname>Da Costa</surname><given-names>C</given-names></name><name><surname>Houddane</surname><given-names>A</given-names></name><name><surname>Dubuis</surname><given-names>S</given-names></name><name><surname>Griffiths</surname><given-names>B</given-names></name><name><surname>Mitter</surname><given-names>R</given-names></name><name><surname>Walz</surname><given-names>S</given-names></name><name><surname>Blake</surname><given-names>S</given-names></name><name><surname>Behrens</surname><given-names>A</given-names></name><name><surname>Brindle</surname><given-names>KM</given-names></name><name><surname>Zamboni</surname><given-names>N</given-names></name><name><surname>Rider</surname><given-names>MH</given-names></name><name><surname>Schulze</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells</article-title><source>Oncogene</source><volume>36</volume><fpage>3287</fpage><lpage>3299</lpage><pub-id pub-id-type="doi">10.1038/onc.2016.477</pub-id><pub-id pub-id-type="pmid">28092678</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoors</surname><given-names>S</given-names></name><name><surname>De Bock</surname><given-names>K</given-names></name><name><surname>Cantelmo</surname><given-names>AR</given-names></name><name><surname>Georgiadou</surname><given-names>M</given-names></name><name><surname>Ghesquière</surname><given-names>B</given-names></name><name><surname>Cauwenberghs</surname><given-names>S</given-names></name><name><surname>Kuchnio</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>BW</given-names></name><name><surname>Quaegebeur</surname><given-names>A</given-names></name><name><surname>Goveia</surname><given-names>J</given-names></name><name><surname>Bifari</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Tembuyser</surname><given-names>B</given-names></name><name><surname>Cornelissen</surname><given-names>I</given-names></name><name><surname>Bouché</surname><given-names>A</given-names></name><name><surname>Vinckier</surname><given-names>S</given-names></name><name><surname>Diaz-Moralli</surname><given-names>S</given-names></name><name><surname>Gerhardt</surname><given-names>H</given-names></name><name><surname>Telang</surname><given-names>S</given-names></name><name><surname>Cascante</surname><given-names>M</given-names></name><name><surname>Chesney</surname><given-names>J</given-names></name><name><surname>Dewerchin</surname><given-names>M</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis</article-title><source>Cell Metabolism</source><volume>19</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.11.008</pub-id><pub-id pub-id-type="pmid">24332967</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>YH</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>PFKFB3 regulates oxidative stress homeostasis via its S-glutathionylation in cancer</article-title><source>Journal of Molecular Biology</source><volume>426</volume><fpage>830</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2013.11.021</pub-id><pub-id pub-id-type="pmid">24295899</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shemiakova</surname><given-names>T</given-names></name><name><surname>Ivanova</surname><given-names>E</given-names></name><name><surname>Grechko</surname><given-names>AV</given-names></name><name><surname>Gerasimova</surname><given-names>EV</given-names></name><name><surname>Sobenin</surname><given-names>IA</given-names></name><name><surname>Orekhov</surname><given-names>AN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitochondrial dysfunction and DNA damage in the context of pathogenesis of atherosclerosis</article-title><source>Biomedicines</source><volume>8</volume><elocation-id>166</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines8060166</pub-id><pub-id pub-id-type="pmid">32570831</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Pang</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Phosphorylation of PPARγ at Ser84 promotes glycolysis and cell proliferation in hepatocellular carcinoma by targeting PFKFB4</article-title><source>Oncotarget</source><volume>7</volume><fpage>76984</fpage><lpage>76994</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.12764</pub-id><pub-id pub-id-type="pmid">27769068</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smolders</surname><given-names>VF</given-names></name><name><surname>Zodda</surname><given-names>E</given-names></name><name><surname>Quax</surname><given-names>PHA</given-names></name><name><surname>Carini</surname><given-names>M</given-names></name><name><surname>Barberà</surname><given-names>JA</given-names></name><name><surname>Thomson</surname><given-names>TM</given-names></name><name><surname>Tura-Ceide</surname><given-names>O</given-names></name><name><surname>Cascante</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Metabolic alterations in cardiopulmonary vascular dysfunction</article-title><source>Frontiers in Molecular Biosciences</source><volume>5</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.3389/fmolb.2018.00120</pub-id><pub-id pub-id-type="pmid">30723719</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Kong</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Fang</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Song</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Decreased expression of acetyl-CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma</article-title><source>Cancer Science</source><volume>108</volume><fpage>1338</fpage><lpage>1346</lpage><pub-id pub-id-type="doi">10.1111/cas.13252</pub-id><pub-id pub-id-type="pmid">28387999</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangavelu</surname><given-names>K</given-names></name><name><surname>Chong</surname><given-names>QY</given-names></name><name><surname>Low</surname><given-names>BC</given-names></name><name><surname>Sivaraman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA)</article-title><source>Scientific Reports</source><volume>4</volume><elocation-id>3827</elocation-id><pub-id pub-id-type="doi">10.1038/srep03827</pub-id><pub-id pub-id-type="pmid">24451979</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theodorou</surname><given-names>K</given-names></name><name><surname>Boon</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Endothelial cell metabolism in atherosclerosis</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>6</volume><elocation-id>82</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2018.00082</pub-id><pub-id pub-id-type="pmid">30131957</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Townsend</surname><given-names>N</given-names></name><name><surname>Kazakiewicz</surname><given-names>D</given-names></name><name><surname>Lucy Wright</surname><given-names>F</given-names></name><name><surname>Timmis</surname><given-names>A</given-names></name><name><surname>Huculeci</surname><given-names>R</given-names></name><name><surname>Torbica</surname><given-names>A</given-names></name><name><surname>Gale</surname><given-names>CP</given-names></name><name><surname>Achenbach</surname><given-names>S</given-names></name><name><surname>Weidinger</surname><given-names>F</given-names></name><name><surname>Vardas</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Epidemiology of cardiovascular disease in Europe</article-title><source>Nature Reviews. Cardiology</source><volume>19</volume><fpage>133</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1038/s41569-021-00607-3</pub-id><pub-id pub-id-type="pmid">34497402</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tura</surname><given-names>O</given-names></name><name><surname>Skinner</surname><given-names>EM</given-names></name><name><surname>Barclay</surname><given-names>GR</given-names></name><name><surname>Samuel</surname><given-names>K</given-names></name><name><surname>Gallagher</surname><given-names>RCJ</given-names></name><name><surname>Brittan</surname><given-names>M</given-names></name><name><surname>Hadoke</surname><given-names>PWF</given-names></name><name><surname>Newby</surname><given-names>DE</given-names></name><name><surname>Turner</surname><given-names>ML</given-names></name><name><surname>Mills</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow</article-title><source>Stem Cells</source><volume>31</volume><fpage>338</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1002/stem.1280</pub-id><pub-id pub-id-type="pmid">23165527</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Heuvel</surname><given-names>APJ</given-names></name><name><surname>Jing</surname><given-names>J</given-names></name><name><surname>Wooster</surname><given-names>RF</given-names></name><name><surname>Bachman</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Analysis of glutamine dependency in non-small cell lung cancer: GLS1 splice variant GAC is essential for cancer cell growth</article-title><source>Cancer Biology &amp; Therapy</source><volume>13</volume><fpage>1185</fpage><lpage>1194</lpage><pub-id pub-id-type="doi">10.4161/cbt.21348</pub-id><pub-id pub-id-type="pmid">22892846</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>CC</given-names></name><name><surname>Qian</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>W</given-names></name><name><surname>Tong</surname><given-names>JH</given-names></name><name><surname>To</surname><given-names>K-F</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Go</surname><given-names>MYY</given-names></name><name><surname>Wu</surname><given-names>J-L</given-names></name><name><surname>Cheng</surname><given-names>KW</given-names></name><name><surname>Ng</surname><given-names>SSM</given-names></name><name><surname>Sung</surname><given-names>JJY</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SLC25A22 promotes proliferation and survival of colorectal cancer cells with KRAS mutations and xenograft tumor progression in mice via intracellular synthesis of aspartate</article-title><source>Gastroenterology</source><volume>151</volume><fpage>945</fpage><lpage>960</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.07.011</pub-id><pub-id pub-id-type="pmid">27451147</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wurtz</surname><given-names>P</given-names></name><name><surname>Raiko</surname><given-names>JR</given-names></name><name><surname>Magnussen</surname><given-names>CG</given-names></name><name><surname>Soininen</surname><given-names>P</given-names></name><name><surname>Kangas</surname><given-names>AJ</given-names></name><name><surname>Tynkkynen</surname><given-names>T</given-names></name><name><surname>Thomson</surname><given-names>R</given-names></name><name><surname>Laatikainen</surname><given-names>R</given-names></name><name><surname>Savolainen</surname><given-names>MJ</given-names></name><name><surname>Laurikka</surname><given-names>J</given-names></name><name><surname>Kuukasjarvi</surname><given-names>P</given-names></name><name><surname>Tarkka</surname><given-names>M</given-names></name><name><surname>Karhunen</surname><given-names>PJ</given-names></name><name><surname>Jula</surname><given-names>A</given-names></name><name><surname>Viikari</surname><given-names>JS</given-names></name><name><surname>Kahonen</surname><given-names>M</given-names></name><name><surname>Lehtimaki</surname><given-names>T</given-names></name><name><surname>Juonala</surname><given-names>M</given-names></name><name><surname>Ala-Korpela</surname><given-names>M</given-names></name><name><surname>Raitakari</surname><given-names>OT</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>High-throughput quantification of circulating metabolites improves prediction of subclinical atherosclerosis</article-title><source>European Heart Journal</source><volume>33</volume><fpage>2307</fpage><lpage>2316</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs020</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>N</given-names></name><name><surname>Daiber</surname><given-names>A</given-names></name><name><surname>Förstermann</surname><given-names>U</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Antioxidant effects of resveratrol in the cardiovascular system</article-title><source>British Journal of Pharmacology</source><volume>174</volume><fpage>1633</fpage><lpage>1646</lpage><pub-id pub-id-type="doi">10.1111/bph.13492</pub-id><pub-id pub-id-type="pmid">27058985</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zielke</surname><given-names>HR</given-names></name><name><surname>Sumbilla</surname><given-names>CM</given-names></name><name><surname>Sevdalian</surname><given-names>DA</given-names></name><name><surname>Hawkins</surname><given-names>RL</given-names></name><name><surname>Ozand</surname><given-names>PT</given-names></name></person-group><year iso-8601-date="1980">1980</year><article-title>Lactate: a major product of glutamine metabolism by human diploid fibroblasts</article-title><source>Journal of Cellular Physiology</source><volume>104</volume><fpage>433</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1002/jcp.1041040316</pub-id><pub-id pub-id-type="pmid">7419614</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorova</surname><given-names>LD</given-names></name><name><surname>Popkov</surname><given-names>VA</given-names></name><name><surname>Plotnikov</surname><given-names>EY</given-names></name><name><surname>Silachev</surname><given-names>DN</given-names></name><name><surname>Pevzner</surname><given-names>IB</given-names></name><name><surname>Jankauskas</surname><given-names>SS</given-names></name><name><surname>Babenko</surname><given-names>VA</given-names></name><name><surname>Zorov</surname><given-names>SD</given-names></name><name><surname>Balakireva</surname><given-names>AV</given-names></name><name><surname>Juhaszova</surname><given-names>M</given-names></name><name><surname>Sollott</surname><given-names>SJ</given-names></name><name><surname>Zorov</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mitochondrial membrane potential</article-title><source>Analytical Biochemistry</source><volume>552</volume><fpage>50</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1016/j.ab.2017.07.009</pub-id><pub-id pub-id-type="pmid">28711444</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86260.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>University of Melbourne</institution></institution-wrap><addr-line><named-content content-type="city">Melbourne</named-content></addr-line><country>Australia</country></aff></contrib></contrib-group></front-stub><body><p>In a novel and important approach, the authors have generated coronary artery endothelial cells from thrombectomy specimens of patients with acute myocardial infarctions (AMIECs). Compared to control healthy coronary artery endothelial cells (HCAECs) they display solid evidence for impaired growth, migration and tubulogenesis and major metabolic differences. This advances the field and provides opportunities for future studies including investigating new avenues of therapy for AMI.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.86260.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>University of Melbourne</institution></institution-wrap><addr-line><named-content content-type="city">Melbourne</named-content></addr-line><country>Australia</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Janus</surname><given-names>Edward D</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>University of Melbourne</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Congratulations, we are pleased to inform you that your article, &quot;Endothelial dysfunction in acute myocardial infarction is characterized by cell-autonomous metabolic reprogramming and oxidative stress&quot;, has been accepted for publication in <italic>eLife</italic>.</p><p><italic>Reviewer #1 (Public Review):</italic></p><p>Summary of objectives and findings</p><p>In a novel approach the authors have generated coronary artery endothelial cells from thrombectomy specimens of patients with acute myocardial infarctions (AMIECs). Compared to control healthy coronary artery endothelial cells (HCAECs) they display impaired growth, migration and tubulogenesis and major metabolic differences.</p><p>In a logical sequence of elegant experiments they have shown that AMIECs display augmented reactive oxygen species (ROS) and glutathione intracellular content with low glucose consumption and high lactate production.</p><p>With diminished glycolysis there is shunting towards the pentose phosphate pathway (PPP) and NADPH generation compared with glycolysis in HAECs. The glutaminolytic enzyme GLS was upregulated in AMIECs and explained their high glutamine content. The AMIECs showed a significantly higher mitochondrial membrane potential than the control HCAECs.</p><p>They conclude that high mitochondrial proton coupling underlies the abnormally high production of ROS, balanced by PPP- and glutaminolysis-driven synthesis of glutathione, as a primary, cell-autonomous abnormality driving endothelial dysfunction in AMI.</p><p>Strengths and weaknesses</p><p>The abstract has a very clear and comprehensive summary of the background, methods, results and conclusions. The main body of the manuscript is very well written with an explanation of the context together with results and interpretation for each sub-study and with clear and convincing illustrations for each sub-study. This makes it very easy to read. Strengths include the development of the method to study AMIECs which is a major advance. A weakness is the use of only one batch of commercial cells as a control which may limit the conclusions reached. Another issue is whether the ex vivo AMIECs reflect what happens in vivo. This and potential implications could be discussed.</p><p><italic>Reviewer #3 (Public Review):</italic></p><p>The study provides detailed enzymatic and metabolic analysis of endothelial cells(ECs) derived from myocardial infarction patients and attempts to link these metabolic changes to the slow migration and tubulogenesis phenotype of patient cells. The study it is of great interest to the field of cardiovascular biology and provides the readers with insights into plausible areas of therapeutic interventions to restore functionality of ECs. The study also goes ahead and establishes a cell culture model for 9 patient derived EC lines. The authors demonstrate that AMIECs have reduced glycolytic rates owing to shunting of glucose into the pentose phosphate pathway leading to heightened NADPH production. The NADPH was suggested to be linked to balancing the heightened ROS levels in AMIECs. The authors then go on to demonstrate that AMIECs utilize glutamine as a major carbon source and via its conversion to glutamate, provides for glutathione synthesis.</p><p>The study holds immense merit, however, the authors have missed out on going back and attempting to actually show that the metabolic differences play a major role in contributing to the migration/tubulogenesis defects observed in patient cells, making the study rather descriptive in nature. By attempting to address this concern, the authors will be able to demonstrate that by modulating a few metabolic fluxes in patient endothelial cells, functionality can be restored -- bringing forth the true potential of this very important work. Also, this is an ex-vivo system so the results need to be treated as such. However, this does not discount the crucial findings of the study,</p><p>Additional comments</p><p>The authors have succeeded in producing AMIECs to study and compare with HAECs. This advances the field and provides opportunities for future studies including investigating new avenues of therapy for AMI.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>On page 14 under Methods Endothelial cells – infection should be corrected to infarction</p><p>Please include/clarify how the cells were transported from Edinburgh to Spain and at what stage. Were any of the experiments done in Edinburgh?</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>Specific comments:</p><p>1. It is not clear how the N=3 was achieved if each explant could only be cultured for a certain amount of time and likely only one biopsy sample was obtained from each patient.</p><p>2. In figure 1B, 1C the authors are advised to check the purity of the ECs by Flow cytometry. From the methods, it appears that the cells were derived via explants. To ensure purity, Authors must check for common confounding cell types via Flow cytometry.</p><p>3. Figure numbers are not correct in Figure 1. Figure1D, 1E, 1F need to be checked/corrected.</p><p>4. Figure 3A: Perhaps a better way to represent this data will be to show Lactate and glucose on two separate graphs. The current graph can be very misleading if one does not read the legend. This will be important for the overall improvement of data representation in the paper.</p><p>5. Figure 4: The authors need to treat the cells with a ROS scavenger and check the glutathione levels to positively make the statement they have made about the ROS-Glutathione balance.</p><p>6. The Authors must use inhibitors for Glutaminsase activity and check whether the treatment affects the downstream observations relating to anaplerotic reactions or not. At this point the evidence is mostly extrapolative without confirmatory experiments.</p><p>7. The paper will greatly benefit from simple carbon tracing experiments to show the flow of metabolic fluxes in AMIECs vs controls. The experiments will be conclusive in nature and of great value.</p><p>8. The authors need to utilize drugs to modulate the identified metabolic points- such as PPP /glutamine utilization/ Enhancing glucose uptake/ inhibiting ROS etc. Following such manipulations, the authors must check for phenotypic changes in AMIECs. In case the claim the authors make is correct- that the metabolic differences largely are responsible for the slower migration, the enzymatic manipulations should alter the phenotype towards normalcy.</p></body></sub-article></article>